APLS

Apellis downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded Apellis (APLS) to Neutral from Buy with a $36 price target The firm’s key opinion leader discussions indicate the actual number of geographic atrophy patients that physicians would treat with Apellis’ lead drug, Syfovre or the competitor, Astellas’ Izervay is smaller than anticipated. Goldman sees a slow progressing launch on the forward, saying a lack of clear functional benefit data limits broader uptake. Together these point to a more conservative commercial outlook for Apellis, the analyst tells investors in a research note.

Pick the best stocks and maximize your portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on APLS:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.